Antimicrobial Treatments for Infections
CEO of Neem Biotech, Dr. Graham Dixon discusses the presentations at the American Society for Microbiology (ASM) Conference on Biofilms and the North American Cystic Fibrosis (NACF) Conference on a new way to enhance antibiotic effectiveness by reducing biofilms and bacterial virulence more broadly for the development of novel antimicrobial treatments for infections in chronic wounds and chronic respiratory infections including cystic fibrosis.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Treatment. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Treatment and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Treatment?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Graham Dixon discusses the presentations at the American Society for Microbiology (ASM) Conference on Biofilms and the North American Cystic Fibrosis (NACF) Conference on a new …
- Key Point: Graham Dixon is Neem’s Chief Executive Officer.
- Key Point: He brings with him over 25 years of experience in nurturing biotechnology companies and guiding their novel compounds into and through the clinic.
- Key Point: With a PhD in biochemistry from Swansea University, his R&D track record spans VC-led and publicly-funded biotechnology and pharmaceutical companies in the UK and Europe mor…
- Key Point: Previous experience includes: Onxeo – CSO, Head of R&D; Sensorium – CSO, Head of R&D; Addex – CSO, Head of R&D; and Galapagos – CSO/SVP R&D.
Dr. Graham Dixon is Neem’s Chief Executive Officer. He brings with him over 25 years of experience in nurturing biotechnology companies and guiding their novel compounds into and through the clinic. With a PhD in biochemistry from Swansea University, his R&D track record spans VC-led and publicly-funded biotechnology and pharmaceutical companies in the UK and Europe more broadly.
Previous experience includes: Onxeo – CSO, Head of R&D; Sensorium – CSO, Head of R&D; Addex – CSO, Head of R&D; and Galapagos – CSO/SVP R&D.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

